NCT06649162 A Study to Identify the Risk of Non-alcoholic Fatty Liver Disease (NAFLD) in Patients With Type 2 Diabetes in Clinical Practice and to Evaluate the Clinical Usefulness of Dapagliflozin/Pioglitazone Combination Therapy
| NCT ID | NCT06649162 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Boryung Pharmaceutical Co., Ltd |
| Condition | Type 2 Diabetes |
| Study Type | OBSERVATIONAL |
| Enrollment | 10,000 participants |
| Start Date | 2024-09-30 |
| Primary Completion | 2027-03 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 10,000 participants in total. It began in 2024-09-30 with a primary completion date of 2027-03.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The purpose of this study is to identify the risk of non-alcoholic fatty liver disease (NAFLD) in patients with type 2 diabetes in clinical practice and to evaluate the clinical usefulness of Dapagliflozin/Pioglitazone combination therapy
Eligibility Criteria
Inclusion Criteria: * Among patients with type 2 diabetes, those who are scheduled to administer a fixed-dose combination of dapagliflozin/pioglitazone at baseline (visit 1) * Those who voluntarily signed a written personal information collection and usage agreement after listening to an explanation about the objective and method, etc. of this clinical study. Exclusion Criteria: * Those who have a history of taking a fixed-dose combination of dapagliflozin/pioglitazone at baseline (visit 1). * Those who are expected to need insulin prescription during the study period.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06649162 clinical trial?
This trial is open to participants of all sexes, aged 19 Years or older, studying Type 2 Diabetes. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06649162 currently recruiting?
Yes, NCT06649162 is actively recruiting participants. Contact the research team at syoh@boryung.co.kr for enrollment information.
Where is the NCT06649162 trial being conducted?
This trial is being conducted at Andong, South Korea, Seoul, South Korea.
Who is sponsoring the NCT06649162 clinical trial?
NCT06649162 is sponsored by Boryung Pharmaceutical Co., Ltd. The trial plans to enroll 10,000 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.